Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.

Health technology assessment (Winchester, England)

Volumn 14, Issue Suppl. 2, 2010, Pages 33-39

  Greenhalgh, J ^a   McLeod, C ^b   Bagust, A ^b   Boland, A ^b   Fleeman, N ^b   Dundar, Y ^b   Oyee, J ^b   Dickson, R ^b   Davis, H ^b   Green, J ^b   McKenna, E ^b   Pearson, M ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; PEMETREXED;

COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METASTASIS; PATHOLOGY; REVIEW; UNITED KINGDOM;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; ENGLAND; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; WALES;

EID: 84886943069     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta14suppl2/05     Document Type: Review

References (0)